Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study

Adam S. Kibel, Eli Rosenbaum, Michael W. Kattan, Joel Picus, Robert Dreicer, Eric A. Klein, Gurkamal S. Chatta, Joel B. Nelson, Robert S. DiPaola, Bruce J. Roth, Michael S. Cookson, George Wilding, David F. Jarrard, Tomasz M. Beer, Christopher W. Ryan, Daniel P. Petrylak, Mitchell C. Benson, Alan W. Partin, Elizabeth Garrett-Mayer, Mario A. Eisenberger

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Purpose: Patients with adverse pathological features are at high risk for recurrence following radical prostatectomy. To improve outcomes in this population we performed a phase II study of adjuvant docetaxel in these high risk patients. Materials and Methods: Patients with nonmetastatic radical prostatectomy at greater than 50% risk for recurrence by 3 years were eligible. Pathological findings were centrally reviewed and risk assessment was based on a validated multivariate Cox proportional hazards model. Treatment consisted of 6 cycles of 35 mg/m2 docetaxel weekly given 4 to 12 weeks following surgery. Progression was defined as a prostate specific antigen of 0.4 ng/ml or greater, radiological/pathological evidence of recurrent disease or death from any cause. To screen for the potential benefit of adjuvant weekly docetaxel we used nomogram predicted progression-free survival as a historical control. Results: A total of 77 patients were registered between April 2002 and January 2004. Two patients had grade IV hyperglycemia and 20 had grade III toxicity. At a median followup of 29.2 months (range 1.6 to 39.2) 46 of 76 evaluable cases (60.5%) progressed. Observed median progression-free survival was 15.7 months (95% CI 12.8-25.1). Predicted median progression-free survival in a matched population was 10 months. Seven patients died, including 4 of prostate cancer, 1 with intra-abdominal bleeding during treatment and 2 of pneumonia and sudden cardiac death, respectively, following treatment. Conclusions: Adjuvant docetaxel for prostate cancer is feasible with significant reversible but acceptable toxicity. The actual median progression-free survival of 15.7 months was longer than the nomogram predicted rate for this patient population. Adjuvant docetaxel treatment should be further evaluated in phase III trials in patients with high risk prostate cancer.

Original languageEnglish
Pages (from-to)1777-1781
Number of pages5
JournalJournal of Urology
Issue number5
StatePublished - May 2007

Bibliographical note

Funding Information:
Supported by Sanofi-Aventis.


  • drug therapy
  • mortality
  • prostate
  • prostatectomy
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study'. Together they form a unique fingerprint.

Cite this